Page 55 - Haematologica May 2022

Improved survival after acute GvHD
11.Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363(22):2091-2101.
12. Khoury HJ, Wang T, Hemmer MT, et al. Improved survival after acute graft-versus- host disease diagnosis in the modern era. Haematologica. 2017;102(5):958-966.
13. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on acute GVHD grading. Bone Marrow Transplant. 1995;15(6):825-828.
14. Morishima Y, Sasazuki T, Inoko H, et al. The clinical significance of human leuko- cyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood. 2002;99(11):4200-4206.
15. Petersdorf EW, Gooley TA, Anasetti C, et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood. 1998; 92(10):3515-3520.
16. Sasazuki T, Juji T, Morishima Y, et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program. N Engl J Med. 1998;339(17):1177-1185.
17. Klein SA, Bug G, Mousset S, Hofmann WK, Hoelzer D, Martin H. Long term outcome of patients with steroid-refractory acute intestinal graft versus host disease after treatment with pentostatin. Br J Haematol. 2011;154(1):143-146.
18.Schub N, Günther A, Schrauder A, et al. Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effec- tive. Bone Marrow Transplant. 2011; 46(1):143-147.
19. Schmitt T, Luft T, Hegenbart U, Tran TH, Ho AD, Dreger P. Pentostatin for treatment of steroid-refractory acute GVHD: a retro- spective single-center analysis. Bone Marrow Transplant. 2011;46(4):580-585.
20.Jamani K, Russell JA, Daly A, et al. Prognosis of grade 3-4 acute GVHD contin- ues to be dismal. Bone Marrow Transplant. 2013;48(10):1359-1361.
21. El-Jawahri A, Li S, Antin JH, et al. Improved treatment-related mortality and overall sur- vival of patients with grade IV acute GVHD in the modern years. Biol Blood Marrow Transplant. 2016;22(5):910-918.
22. Horan JT, Logan BR, Agovi-Johnson MA, et al. Reducing the risk for transplantation- related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made? J Clin Oncol. 2011;29(7):805-813.
23. McDonald GB, Sandmaier BM, Mielcarek M, et al. Survival, nonrelapse mortality, and relapse-related mortality after allogeneic hematopoietic cell transplantation: compar- ing 2003-2007 cersus 2013-2017 cohorts. Ann Intern Med. 2020;172(4):229-239.
24. Wolff D, Ayuk F, Elmaagacli A, et al. Current practice in diagnosis and treatment of acute graft-versus-host disease: results from a survey among German-Austrian- Swiss hematopoietic stem cell transplant centers. Biol Blood Marrow Transplant. 2013;19(5):767-776.
25. Van Lint MT, Uderzo C, Locasciulli A, et al. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methyl- prednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood. 1998; 92(7):2288-2293.
26.Mielcarek M, Furlong T, Storer BE, et al. Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trial. Haematologica. 2015; 100(6):842-848.
27. Zeiser R, Blazar BR. Acute graft-versus-host disease - biologic process, prevention, and therapy. N Engl J Med. 2017; 377(22):2167- 2179.
28. Zeiser R, Burchert A, Lengerke C, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter sur- vey. Leukemia. 2015;29(10):2062-2068.
29. Kennedy GA, Varelias A, Vuckovic S, et al. Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem- cell transplantation: a phase 1/2 trial. Lancet Oncol. 2014;15(13):1451-1459.
30.Koreth J, Stevenson KE, Kim HT, et al. Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allo- geneic stem cell transplantation from HLA- mismatched unrelated donors. Blood. 2009;114(18):3956-3959.
31. Tawara I, Sun Y, Lewis EC, et al. Alpha-1- antitrypsin monotherapy reduces graft- versus-host disease after experimental allogeneic bone marrow transplantation. Proc Natl Acad Sci U S A. 2012;109(2):564- 569.
32. Koura DT, Horan JT, Langston AA, et al. In vivo T cell costimulation blockade with abatacept for acute graft-versus-host dis- ease prevention: a first-in-disease trial. Biol Blood Marrow Transplant. 2013;19(11): 1638-1649.
33. Reshef R, Luger SM, Hexner EO, et al. Blockade of lymphocyte chemotaxis in vis-
ceral graft-versus-host disease. N Engl J
Med. 2012;367(2):135-145.
34. Martelli MF, Di Ianni M, Ruggeri L, et al.
HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. Blood. 2014;124(4):638-644.
35. Anasetti C, Logan BR, Lee SJ, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012;367(16):1487-1496.
36. Eapen M, Logan BR, Appelbaum FR, et al. Long-term survival after transplantation of unrelated donor peripheral blood or bone marrow hematopoietic cells for hematolog- ic malignancy. Biol Blood Marrow Transplant. 2015;21(1):55-59.
37. Lee SJ, Logan B, Westervelt P, et al. Comparison of patient-reported outcomes in 5-Year survivors who received bone mar- row vs peripheral blood unrelated donor transplantation: long-term follow-up of a randomized clinical trial. JAMA Oncol. 2016;2(12):1583-1589.
38. Kröger N. Induction, bridging, or straight ahead: the ongoing dilemma of allografting in advanced myelodysplastic syndrome. Biol Blood Marrow Transplant. 2019; 25(8):e247-e249.
39.Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017; 129(4):424-447.
40. Scott BL, Pasquini MC, Logan BR, et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 2017;35(11):1154- 1161.
41. Festuccia M, Deeg HJ, Gooley TA, et al. Minimal identifiable disease and the role of conditioning intensity in hematopoietic cell transplantation for myelodysplastic syn- drome and acute myelogenous leukemia evolving from myelodysplastic syndrome. Biol Blood Marrow Transplant. 2016; 22(7):1227-1233.
42. Luznik L, O'Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow trans- plantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophos- phamide. Biol Blood Marrow Transplant. 2008;14(6):641-650.
43. Nagler A, Labopin M, Dholaria B, et al. Comparison of haploidentical bone mar- row versus matched unrelated donor peripheral blood stem cell transplantation with post-transplant cyclophosphamide in patients with acute leukemia. Clin Cancer Res. 2021;27(3):843-851.
haematologica | 2022; 107(5)
1063